Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21

Tianyang Xu; Wenwei Jiang; Lin Fan; Qiuming Gao; Guodong Li

doi:10.18632/oncotarget.20738

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21

Tianyang Xu, Wenwei Jiang, Lin Fan, Qiuming Gao and Guodong Li _

PDF | HTML | How to cite

Oncotarget. 2017; 8:101406-101417. https://doi.org/10.18632/oncotarget.20738

Metrics: PDF 1436 views | HTML 2355 views | ?

Abstract

Tianyang Xu1,*, Wenwei Jiang1,*, Lin Fan1, Qiuming Gao1 and Guodong Li1

1Department of Orthopedics, Shanghai Tenth People’s Hospital, Tong Ji University School of Medicine, Shanghai 200072, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Guodong Li, email: [email protected]

Keywords: osteosarcoma; Xist; proliferation; EZH2; P21

Received: April 25, 2017 Accepted: August 07, 2017 Published: September 08, 2017

ABSTRACT

Recent studies show that lncRNAs involve in the initiation and progression of various cancers including osteosarcoma (OS). IncRNA Xist has been verified as an oncogene in several human cancers, and its abnormal expression was closely associated with tumor initiation and progression. Nevertheless, the role of Xist in OS remains unclear. Here, we revealed the Xist expression level was up-regulated in OS tissues and discovered that Xist knockdown significantly repressed OS cell proliferation. Additionally, mechanistic analysis revealed that Xist can repress P21 expression to regulate OS cell cycle and proliferation by binding to EZH2. Taking all into account, Xist may function in promoting OS cell proliferation and may potentially serve as a novel biomarker and therapeutic target for OS.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20738

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21

Abstract